Shares of TransMedics Group TMDX moved higher in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 46.51% over the past year to ($0.23), which beat the estimate of ($0.25).
Revenue of $7,627,000 up by 25.92% from the same period last year, which beat the estimate of $6,040,000.
Guidance
TransMedics Group hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Mar 02, 2021
Time: 04:30 PM
Technicals
Company's 52-week high was at $41.20
Company's 52-week low was at $10.10
Price action over last quarter: Up 203.26%
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes the technology to replicate near-physiologic conditions for donor organs outside of the human body.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.